Growth trajectory CareDx reports growing revenue with a Q2 run-rate around $132M and trailing revenue near $380M, signaling an expanding market opportunity in transplant diagnostics that sales teams can target with integrated precision solutions and bundled offerings.

High gross leverage Gross margins are robust (78% historically, 74% non-GAAP in the latest period), indicating strong profitability potential for new product deployments or service expansions that can maintain or improve margin profiles when selling enhanced care pathways.

Strategic pivot Recent asset divestitures in the lab products space and a planned acquisition of Naveris suggest a strategic realignment toward high-value diagnostics and MRD surveillance, presenting cross-sell and upsell opportunities for advanced sequencing, analytics, and surveillance services.

Transplant focus A clear transplant-centered mission and active participation in major conferences with multiple abstracts and presentations indicate ongoing thought leadership and demand generation channels to leverage for client education, pilots, and scalable deployment of precision diagnostics.

Partnership potential Industry peers with similar scale and focus (e.g., large diagnostics and molecular labs) present collaboration prospects for co-development, data-sharing partnerships, and expanded contract manufacturing or service offerings to extend CareDx’s reach in transplant care ecosystems.